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V-B.04 MODIFIED ROBOTIC APPLEBY
PROCEDURE WITH LEFT
NEPHRECTOMY AND
ADRENALECTOMY FOR
LOCALLY ADVANCED DISTAL
PANCREATIC CANCER
M. Radomski, A. Zureikat, H. Zeh, M. Hogg
University Of Pittsburgh, Pittsburgh, PA
Patients presenting with Stage III pancreatic adenocarcinoma
involving the distal pancreas and celiac axis have historically
been treated by nonsurgical means. However, almost a third
of these patients will die without metastatic disease suggest-
ing that aggressive surgical resection involving visceral vas-
cular structures may offer a survival advantage. Appleby first
described resection of the celiac axis for gastric cancer. We
have extended this technique to include stage III distal pan-
creatic adenocarcinoma involving the celiac axis without evi-
dence of metastatic disease via a combined laparoscopic and
robotic approach. We describe a robotic distal pancreatec-
tomy, splenectomy, left nephrectomy, and left adrenalectomy
in a 65 year old female patient with pancreatic adenocarci-
noma involving the distal pancreas without evidence of
distant metastatic disease. She previously underwent six
cycles neoadjuvant chemotherapy with gemcitabine and
abraxane in which she had a good response with normalizing
CA19-9 values. Her postoperative course was complicated
by gastric ischemia which was treated with short course of
total parenteral nutrition, and a portal vein thrombus treated
with subcutaneous low molecular weight heparin. Her
pathology showed a 4.0 cm moderately differentiated adeno-
carcinoma with negative margins and twenty-six lymph
nodes negative for disease. She was discharged home on
postoperative day 25 and started on adjuvant chemotherapy
with gemcitabine and abraxane on postoperative day 76.
V-B.05 ROBOTIC
PANCREATICODUODENECTOMY WITH
PORTAL VEIN RESECTION AND PATCH
VENOPLASTY
M. Girgis, M. Hogg, H. Zeh, A. Zureikat
University Of Pittsburgh School Of Medicine, Pittsburgh,
PA
Introduction: Robotic pancreaticoduodenectomy is safe
and feasible for resectable pancreatic head adenocarcinoma.
Vascular resection during pancreaticoduodenectomy for
borderline resectable PDAC may be associated with slightly
increased morbidity but provides good oncologic outcomes.
We describe a robotic pancreaticoduodenectomy with
planned portal vein resection and patch venoplasty in a
patient with borderline resectable pancreas cancer.
Methods: This patient’s operation was recorded by the Da
Vinci Surgical System. The file footage was compiled and
edited. The patient’s consent was obtained.
Results: This is the case of a 57-year-old patient with
locally advanced pancreas cancer. He underwent 6 cycles of
neoadjuvant chemotherapy. Restaging CT scan showed
down-staging of the tumor to borderline resectable status.
The procedure was completed robotically in 452 minutes
with an estimated blood loss of 900 ml. A large 4 cm partial
portal vein resection was performed with reconstruction
using bovine pericardium in the form of a patch venoplasty.
Final pathology revealed a 2.9 cm tumor with 4/37 nodes
positive. He recovered uneventfully from the surgery and was
discharged from the hospital on postoperative day 6. Within
45 days of surgery, he had initiated adjuvant chemotherapy.
Conclusions: We describe a robotic portal vein resection
and reconstruction with patch venoplasty for borderline
resectable PDAC. We were able to complete the procedure
safely and in a timely manner with minimal morbidity.
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LO-J.01 ELEVATED INR
INDEPENDENTLY PREDICTS MAJOR
COMPLICATIONS FOLLOWING MAJOR
HEPATECTOMY
J. N. Leal, T. P. Kingham, P. J. Allen, R. P. DeMatteo,
W. R. Jarnagin, M. I. D’Angelica
Memorial Sloan Kettering Cancer Center, New York, NY
Background: The impact of major hepatectomy on
hemostasis is poorly characterized and accuracy of INR as an
indicator of coagulation status in the peri-operative setting
is unknown. This study aimed to characterize post-
hepatectomy hemostatic profiles and to evaluate subsequent
impact on clinical outcomes.
Methods: All patients undergoing major hepatectomy
between 2001–2012 were identified from a prospective data-
base. Clinicopathologic and blood product transfusion data
were extracted. Post-operative hemostatic profiles were
analyzed with respect to plasma transfusion and major com-
plications.
Results: 961 patients were identified. The mean number
of Couinaud segments resected was 4.3(+/−0.85).Post-
operatively peak INR was 1.50 +/− 0.26, platelet nadir
166.1 +/− 61.7 K/mcL, and hemoglobin nadir 9.5 +/− 1.34 g/
dL. INR ≥1.8 occurred in 152 (16%) patients. Major bleeding
complication rates in the INR ≥1.8 group were not different
from INR <1.8 group (0.7% vs. 0.8%, p = 0.90). Alterna-
tively, major complication rates were significantly higher
(37% INR ≥1.8 vs. 17% INR <1.8, p < 0.0001). Among the
INR ≥1.8 group, plasma was transfused in 66% of cases and
was not associated with a significant change in major com-
plication rates (40% in peak INR ≥1.8 with plasma vs. 30%
in peak INR ≥1.8 without plasma, p = 0.30). On multivariate
analysis, including standard variables, peak INR ≥1.8 was
independently associated with major complications (OR
2.48, 95% CI 1.64–3.74, p < 0.0001) while FFP transfusion
was not (OR 1.35 95% CI 0.90–2.05, p = 0.152).
Conclusions: Elevated INR following major hepatectomy
does not increase the risk of post operative hemorrhage but
rather portends increased overall morbidity that is not miti-
gated by FFP transfusion.
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LO-J.02 EARLY INCREASES IN
POSTOPERATIVE SERUM
PHOSPHOROUS AND CREATININE
LEVELS ARE ASSOCIATED WITH
MORTALITY FOLLOWING
MAJOR HEPATECTOMY
G. Herbert1, W. Jarnagin1, R. DeMatteo1, P. Allen1,
M. D’Angelica1, M. Gonen1, K. Prussing2, T. P. Kingham1
1Memorial Sloan Kettering Cancer Center, New York, NY;
2University Of Minnesota Medical School, Duluth, MN
Introduction: Post-hepatectomy liver failure (PHLF) is
defined by the International Study Group of Liver Surgery as
a bilirubin >2.9 mg/dL and INR >1.7 on or after postopera-
tive day 5 (the 50/50 criteria), and greatly increases the risk
of death after hepatectomy. Other than pre-existing liver
disease and small future liver remnant, few patient factors or
early post-operative indicators identify patients at elevated
risk of PHLF.
Methods: We reviewed demographics, comorbidities,
operative procedures, and post-operative laboratory trends of
patients undergoing major hepatectomy (>= 3 Couinaud seg-
ments) for malignancy from 1998–2013 at our institution.
These factors were compared between patients dying within
90 days of surgery, survivors meeting the 50/50 criteria, and
all remaining survivors.
Results: 1536 patients underwent major hepatectomy
during the time period. The majority were performed for
metastatic colorectal cancer, with an average of 4.24 resected
segments. 49 (3.2%) died within 90 days of surgery. 47
(3.1%) patients met ISGLS criteria for PHLF, of whom 15
died within 90 days of surgery. Operative blood loss was
twice as high in patients dying within 90 days as compared to
survivors. In spite of greater perioperative resuscitation
(achieving equivalent urine output) when compared to survi-
vors, non-survivors had significantly higher creatinine and
phosphorous levels on POD 1. Predicted residual liver
volume did not differ between patients dying within 90 days
and survivors who met the 50/50 criteria (32.1% vs 31.1%).
Conclusions: An increase in both creatinine and phospho-
rous on POD 1 is an early indicator of patients at risk for
PHLF.
LO-J.03 EFFECTS OF BLOOD
TRANSFUSION ON PERIOPERATIVE
AND LONG-TERM OUTCOMES AFTER
MAJOR HEPATECTOMY FOR
METASTATIC COLORECTAL CANCER:
A MULTI-INSTITUTIONAL STUDY OF
456 PATIENTS
L. M. Postlewait1, M. H. Squires1, D. A. Kooby1,
S. M. Weber2, C. R. Scoggins3, K. Cardona1, C. S. Cho2,
R. C. Martin3, E. Winslow2, S. K. Maithel1
1Division Of Surgical Oncology, Emory University, Atlanta,
GA; 2Division Of Surgical Oncology, University Of
Wisconsin, Madison, WI; 3Division Of Surgical Oncology,
University Of Louisville, Louisville, KY
Background: Data on the prognostic implications of blood
transfusion at the time of major hepatectomy (≥3 segments)
for colorectal cancer metastases are conflicting. Our aim was
to assess the association of perioperative transfusion with
postoperative complications and disease-specific survival
(DSS).
Methods: Patients who underwent major hepatectomy for
metastatic colorectal cancer from 2000–2010 at three US
academic institutions were included. 30-day mortalities and
patients who died of unknown cause were excluded from
survival analyses. Transfusion was analyzed based on timing
and volume of transfusion.
Results: Of 456 patients, 140 (30.7%) received blood trans-
fusions. Perioperative transfusion was associated with
extended hepatectomy (40.8%vs27.9%; p = 0.020),
increased tumor size (5.7 vs 4.2 cm; p < 0.001), and
increased estimated blood loss (917 vs 390 mL; p < 0.001).
There were no differences between patients with or without
transfusion regarding age, ASA class, margin, number of
lesions, cirrhosis, or lymphovascular invasion. On multivari-
ate analysis, perioperative transfusion was associated with
major complications (HR3.14; 95%CI: 1.83–5.39; p < 0.001)
and 90-day readmission (HR2.14; 95%CI: 1.18–3.89;
p = 0.012). 388 patients were included in survival analyses;
median follow-up was 38.8 mos. Perioperative transfusion
was not associated with DSS; however, patients who received
blood postoperatively had decreased DSS (37.4 vs
42.7 mos;p = 0.044). Increasing volume of transfusion at any
time was associated with shortened DSS (Perioperative: 0
units: 42.1 vs 1–2 units: 39.6 vs ≥3 units: 37.4 mo, p = 0.046;
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Postoperative: 0 units: 42.7 vs 1–2 units: 38.6 vs ≥3 units:
27.2 mo, p = 0.031; Figure). Transfusion, regardless of
timing and volume, was not independently associated with
worsened DSS on multivariate analyses.
Conclusion: Perioperative blood transfusion with major
hepatectomy for colorectal cancer metastases is indepen-
dently associated with increased complications and readmis-
sion but not reduced disease-specific survival. Judicious use
of blood transfusion in the perioperative period is warranted.
LO-J.04 THE ACCURACY OF
PREOPERATIVE IMAGING AND
INTRAOPERATIVE FROZEN
SECTION IN THE MANAGEMENT
OF HEPATIC CYSTS
A. Doussot1, B. Groot Koerkamp1, P. J. Allen1,
R. P. De Matteo1, J. Shia2, T. P. Kingham1, W. R. Jarnagin1,
S. R. Gerst3, M. I. D’Angelica1
1Department Of Surgery Memorial Sloan Kettering Cancer
Center, New York, NY; 2Department Of Pathology
Memorial Sloan Kettering Cancer Center, New York, NY;
3Department Of Radiology Memorial Sloan Kettering
Cancer Center, New York, NY
Introduction: Biliary cystic tumors (BCT) (biliary
cystadenoma (BCA) and cystadenocarcinoma (BCAC))
warrant complete resection. Simple liver cysts (SLC),
however, require only fenestration if symptomatic. Distin-
guishing between BCT and SLC with preoperative imaging
is not well studied.
Methods: All patients undergoing surgery for a preoperative
diagnosis of SLC or BCT were included. Perioperative clini-
cal and imaging features from radiology reports were
analyzed for their ability to predict the final diagnosis.
Results: Ninety four patients underwent fenestration
(n = 53), enucleation (n = 6) or liver resection (n = 35) for
suspected SLC (n = 54), BCA (n = 32) and BCAC (n = 8).
Final pathologic diagnoses were SLC (n = 73), BCA
(n = 15), BCAC (n = 3) and other primary liver cancers
(n = 3). On multivariate analysis, preoperative imaging fea-
tures such as solitary lesion, septations and solid component
were associated with a final diagnosis of BCT (p < 0.05;
Table). However, one-third of SLC presented with septations
or solitary lesions. Five patients (23.8%) were initially mis-
diagnosed as SLC and 24 patients (32.9%) were misdiag-
nosed as BCT of which 15 patients unnecessarily underwent
resection. Fenestration and frozen section (FS) was per-
formed in 47 patients (diagnostic accuracy = 100%),
impacting surgical management in 12 patients (12.7%) by
avoiding (n = 8) or mandating (n = 4) liver resection. No
patients with BCT (n = 8), submitted to fenestration and FS
followed by resection, developed recurrence.
Conclusion: Worrisome imaging features are associated
with a higher risk of BCT. However, one-third of patients
with SLC present with such imaging characteristics. In the
absence of a strong suspicion of malignancy, fenestration and
FS should be considered prior to complete resection.
LO-J.05 THE IMPACT OF PORTAL
PEDICLE CLAMPING ON SURVIVAL
FROM COLORECTAL LIVER
METASTASES IN THE CONTEMPORARY
ERA OF LIVER RESECTION: A
MATCHED COHORT STUDY
M. E. Tsang1, P. J. Karanicolas1,2, R. Habashi1, E. Cheng1,
S. Hanna1,2, N. G. Coburn1,2, C. H. Law1,2, J. Hallet2
1Division Of General Surgery, University Of Toronto,
Toronto, ON; 2Sunnybrook Health Sciences Centre – Odette
Cancer Centre, Toronto, ON
Introduction: Portal pedicle clamping (PPC) reduces bleed-
ing during hepatectomy, but may impact micro-metastases’
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growth through ischemia-reperfusion injury. We sought to
examine the association between PPC and long-term survival
following hepatectomy for colorectal liver metastases
(CRLM).
Methods: We conducted a matched cohort study using our
prospective hepatectomy database to identify all patients
undergoing hepatectomy for CRLM from 2003 to 2013.
Cohorts were selected based on use of PPC, with 1 : 1 match-
ing for age (5-year increments), time period (2003–2007 vs.
2007–2013), and Clinical Risk Score (0 to 5 scale). Primary
outcome was overall survival (OS). Conditional logistic and
Cox regression analyses determined odds ratios (OR) and
hazard ratios (HR).
Results: Of 481 hepatectomies for CRLM, 187 (39%)
patients underwent PPC. 110 pairs of patients were matched
in the cohorts, and the remainder excluded. Peri-operative
chemotherapy (p = 0.183), major hepatectomy (>= 3 seg-
ments) (p = 0.345) or resection status (R0 vs. R1–2)
(p = 0.132) did not differ. 30-day major morbidity (OR 0.73;
p = 0.332) and mortality (OR 2.4; p = 0.100) were not sig-
nificantly associated with PPC. Median follow-up was 35
(range: 0–130) months. When adjusting for extent of resec-
tion, blood loss, and operative time, no significant difference
was observed in OS (HR 1.76; p = 0.129) for PPC, with
5-year OS of 59.2% (95%CI: 54.0–59.2%) for PPC and
62.3% (95%CI: 61.8–67.3%) without PPC (log-rank
p = 0.415). Excluding 90-day deaths did not substantially
alter the results (log-rank p = 0.930).
Conclusions: PPC was not associated with a significant dif-
ference in OS in patients undergoing hepatectomy for
CRLM. It does not appear to adversely affect oncologic
outcomes.
LO-J.06 HEPATO-PANCREATECTOMY:
HOW MORBID? RESULTS FROM THE
NATIONAL SURGICAL QUALITY
IMPROVEMENT PROGRAM
T. B. Tran, M. M. Dua, D. A. Spain, B. C. Visser,
J. A. Norton, G. A. Poultsides
Stanford University School Of Medicine, Stanford, CA
Background: Simultaneous resection of both the liver and
pancreas carries significant complexity. The objective of this
study is to investigate perioperative outcomes following syn-
chronous hepatectomy and pancreatectomy (SHP).
Methods: The American College of Surgeons National
Surgical Quality Improvement Program (ACS-NSQIP)
database was queried to identify patients who underwent
SHP. Resections were defined as follows: “<hemihe-
patectomy”, “≥hemihepatectomy” (hemihepatectomy and
trisectionectomy), “PD” (pancreaticoduodenectomy), and
“distal” (distal pancreatectomy and enucleation).
Results: From 2005 to 2012, 377 patients underwent SHP,
representing 1% of 38,568 patients who underwent hepatec-
tomy and/or pancreatectomy. Median age was 60 years. Indi-
cations included pancreatic malignancy (60%), hepatobiliary
malignancy (10%), benign disease (6%), gastric cancer (4%),
retroperitoneal neoplasm (3%), colon cancer (2%), and other
(15%). Patients were stratified based on the extent of com-
bined resection: <hemihepatectomy + distal (n = 170),
≥hemihepatectomy + distal (n = 37), <hemihepatectomy +
PD (n = 151), and ≥hemihepatectomy + PD (n = 19).
Perioperative morbidity and mortality gradually increased as
resections became more extensive (Figure). Although the
first 3 groups had a reasonable morbidity and mortality
profile, in the latter group of ≥hemihepatectomy + PD the
rate of any complication was 84%, septic shock 26%,
reintubation 16%, hemodialysis 10%, 30-day mortality 10%,
and in-hospital mortality 33%.
Conclusions: Liver resections less extensive than hemi-
hepatectomy can be performed concurrently with any pan-
createctomy resulting in an acceptable safety profile. Syn-
chronous hemihepatectomy (or trisectionectomy) and
pancreaticoduodenectomy remains a highly morbid combi-
nation and should be reserved for patients who have under-
gone extremely cautious selection.
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LO-J.07 PORTAL VEIN EMBOLISATION
AND APPLICATION OF
HAEMATOPOIETIC STEM CELLS IN
PRIMARILY NON-RESECTABLE
COLORECTAL LIVER METASTASES
FOR INSUFFICIENT FUTURE LIVER
REMNANT VOLUME
V. Treska1,2
1University Hospital, Pilsen, PILSEN; 2School Of
Medicine, Pilsen, PILSEN
Background: Insufficient future liver remnant volume
(FLRV) is the cause of the low resectability of colorectal
liver metastases (CLMs).Portal vein embolisation (PVE)
with the application of autologous haematopoietic stem cells
(HSCs) is option for increasing resectability of CLMs. The
aim of our study was to compare the effect of PVE only and
PVE with application of HSCs in patients with primarily
non-resectable CLMs due to insufficient FLRV.
Methods: In prospective, randomised study PVE with the
application of HSCs was used in 14 patients (GI). The control
group (GII) consisted of 14 patients in whom only PVE was
performed. We evaluated FLRV growth, CLM volume
growth, median survival and progression-free survival (PFS).
Results: In all GI patients sufficient FLRV growth occurred
within three weeks. In the first two weeks, FLRV increased in
most of the patients (p < 0.006). In 13 (92.9%) of the GII
patients, optimum FLVR growth was observed within three
weeks following PVE (p < 0.002). More rapid FLVR growth
was observed in the GI patients (p < 0.01). CLM volume was
significantly increased in the GII (p < 0.0005) and also GI
(p < 0.006) at the time of liver resection. There was no sig-
nificant difference in the growth of the CLM volume between
the groups (p < 0.17). The median survival of the GI and GII
patients was 7.4 and 6.8 months and the two-year PFS was 27
and 22% (n.s.), respectively.
Conclusion: We can conclude that PVE with HSC applica-
tion is a promising method for effectively stimulating FLVR
growth in primarily non-resectable CLMs.
LO-J.08 ENHANCED ULTRASOUND
WITH NAVIGATION LEADS TO
IMPROVED LIVER LESION
IDENTIFICATION AND
NEEDLE PLACEMENT
R. C. Martin
University Of Louisville, Louisville, KY
Background: The aim of this study was to evaluate whether
3-dimensional (3D) enhanced ultrasound could increase the
accuracy and efficiacy for liver tumor identification and
needle placement.
Methods: A prospective study of 30 surgeons of various
training level where evaluated lesion identification success
and accuracy of needle placement. All surgeons were evalu-
ated for time(seconds) to identify the liver lesions and place-
ment of needles after review of 3 phase CT scan of the liver
and using standard B-mode ultrasound and then enhanced 3D
ultrasound (E-3DUS).
Results: Participants included 10 HPB surgeons, 5 Surgical
Fellows, 10 PGY-4&5 Surgical Residents and 5 PGY-3 resi-
dents. Liver lesions were correctly identified in 73% of the
cases using B-mode ultrasound alone and 100% in E-3DUS.
The Mean time to identification is B-mode was 51.9 seconds
(SD +/− 37.1), which was significantly longer than with
E-3DUS (time 17.9 seconds, SD +/− 10.7)(p = 0.002). There
was significant improvement in time to lesion identification
using E-3DUS across all training levels (Figure,
*-P < 0.002). There was also a significant reduction in time
for accurate needle placement across all training levels (mean
reduction of 60%, within enhanced accuracy (p = 0.001)
Conclusions: E-3DUS significantly enhances lesion identi-
fication regardless of size and enhances needle accuracy for
all surgeons. This adjunctive system should be considered for
both training as well as for all complex liver tumor ablations.
MO-A.02 BRANCHED DNA ENHANCED
ALBUMIN RNA IN SITU
HYBRIDIZATION PROVIDES A
DEFINITIVE DIAGNOSIS FOR
INTRAHEPATIC
CHOLANGIOCARCINOMA
C. R. Ferrone, D. T. Ting, M. Shahid, I. T. Konstantinidis,
L. Goyal, N. Bardeesey, D. Borger, K. D. Lillemoe,
A. X. Zhu, M. N. Rivera, V. Deshpande
Massachusetts General Hospital, Boston, MA USA
Purpose: Intrahepatic cholangiocarcinoma (ICC) is often a
diagnosis of exclusion after patients have undergone numer-
ous studies and procedures. Currently there is no
histopathologic or immunohistochemical marker for ICC.
Albumin expression is restricted to the liver. Since liver
parenchymal cells are derived from a common embryonic
progenitor, the aim of our study was to determine if albumin
is a potential biomarker for ICC utilizing a novel and highly
sensitive RNA in situ hybridization (ISH) platform.
Methods: Modified branched DNA probes were developed
for albumin RNA ISH. A total of 467 patient samples of
primary and metastatic lesions were evaluated.
Results: Of the 467 samples, 43 were ICCs, 42 were hepa-
tocellular carcinomas and 332 were non-hepatic carcinomas
including tumors arising from the perihilar region, bile duct,
pancreas, stomach, esophagus, colon, lung, breast, ovary,
endometrium, kidney, and urinary bladder. Albumin RNA
ISH was highly sensitive for cancers of liver origin, staining
positive in 42 of 43 ICCs (99%) and 42 HCCs (100%).
Perihilar and distal bile duct carcinomas as well as carcino-
mas arising at other sites were negative for albumin. Notably,
6 of 27 (22%) intrahepatic tumors previously diagnosed
as carcinomas of undetermined origin were positive for
albumin.
Conclusions: Albumin RNA ISH is a sensitive and highly
specific diagnostic tool to distinguish ICC from metastatic
adenocarcinoma to the liver or carcinoma of unknown origin.
The specificity of albumin RNA ish could replace the exten-
sive diagnostic work up patients undergo to confirm the
diagnosis.
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MO-A.03 HIGH HLA CLASS I ANTIGEN
EXPRESSION IN COMBINATION WITH
LOW PD-L1 EXPRESSION AS A
FAVOURABLE PROGNOSTIC
BIOMARKER IN INTRAHEPATIC
CHOLANGIOCARCINOMA
F. Sabbatino1, V. Villani1, J. H. Yearley2, L. Cai1,
V. Deshpande3, I. T. Konstantinidis1, S. P. Nota4, Y. Wang1,
A. X. Zhu5, L. Goyal5, D. T. Ting5, N. M. El-Bardeesy5,
T. S. Hong6, K. K. Tanabe7, C. Moon2, S. Ferrone1,4,
K. D. Lillemoe1, C. R. Ferrone1
1Department Of Surgery, Massachusetts General Hospital,
Boston, MA; 2Merck Research Laboratories, Palo Alto,
CA; 3Department Of Pathology, Massachusetts General
Hospital, Boston, MA; 4Department Of Orthopedic
Surgery, Massachusetts General Hospital, Boston, MA;
5Cancer Center, Massachusetts General Hospital, Boston,
MA; 6Department Of Radiation Oncology, Massachusetts
General Hospital, Boston, MA; 7Department Of Surgical
Oncology, Massachusetts General Hospital, Boston, MA
Introduction: For immune checkpoint molecule-specific
monoclonal-antibodies (mAbs) to be effective patients must
be able to mount an immune response to their tumor. This
requires a functional HLA class I antigen-processing machin-
ery in the targeted tumor cells. We evaluated i) lymphocyte
infiltrate as a measure of a patient’s immune response to their
intrahepatic cholangiocarcinoma (ICC) ii) HLA class I
antigen expression iii) expression of the checkpoint mol-
ecules programmed cell death 1 (PD-1) and its primary
ligand programmed cell death ligand 1 (PD-L1).
Methods: Clinicopathologic data for 30 patients under-
going resection for ICC was collected. Tumors were
immunohistochemically stained with CD8-, CD4-, HLA-,
PD-1- and PD-L1-specific mAbs.
Results: Median age was 64 years, 47% had stage II disease
and median follow-up was 28.1 months. All tumors had
lymphocyte infiltrates. CD8s in the fibrous septa (FS)
between tumor lobules (TL) was higher than within TL
(mean 104 vs 12, P < 0.0001), but not for CD4s. CD8s and
CD4s in the FS and TL correlated with HLA expression
(P < 0.05). CD8s were decreased, while CD4s were
increased if HLA was down-regulated. PD-1 expression was
present in 83% of cases and highest on T cells in the FS.
CD8s/CD4s, HLA, and PD-1/PD-L1 expression in the tumor
microenvironment did not correlate with survival. In contrast
high HLA expression and low PD-L1 expression was asso-
ciated with a longer overall survival (P = 0.04).
Conclusions: Increased PD-L1 expression and HLA class I
antigen defects provide ICC with an escape mechanism from
immune recognition. This provides rationale for implement-
ing antibodies to checkpoint molecules for ICC.
MO-A.04 PIVOTAL ROLE OF INTRA-
PLATELET VEGF-A DURING
ANGIOGENIC PHASE OF LIVER
REGENERATION AFTER PARTIAL
HEPATECTOMY IN HUMANS
B. Aryal1, T. Shimizu2, J. Kadono1, A. Furoi3,
M. Yamakuchi2, M. Inoue1, T. Komokata4, T. Hashiguchi2,
Y. Imoto1
1Cardiovascular And Gastroenterological
Surgery,Kagoshima University, Kagoshima, KYUSHU
Japan; 2Laboratory And Vascular Medicine, Kagoshima
University, Kagoshima, KYUSHU Japan; 3Kirishima
Medical Center, Kirishima, KYUSHU Japan; 4Kagoshima
Medical Center, Kagoshima, KYUSHU Japan
The ability of remnant liver to regenerate plays a decisive
role in morbidity and mortality after liver resection. Molecu-
lar mechanism of liver regeneration (LR) has still remained
as a major concern in modulating the strategies in order to
improve the outcome after resection. Two phases of LR have
been proposed lately; inductive phase marked by rapid pro-
liferation of hepatocytes followed by a delayed angiogenic
phase with proliferation of non-parenchymal cells. Several
studies have already reported the beneficial role of platelet in
LR. We introduce platelet as a central player in the
angiogenic phase of LR after partial hepatectomy in human.
Materials and Methods: Twenty patients with diagnosed
hepatocellular carcinoma; eligible for hepatectomy were
enrolled in the study. Serum, plasma and intra-platelet
VEGF-A (vascular endothelial growth factor-A) along with
the major mitogens were monitored both before and after one
month of operation.
Result: The major serum VEGF-A pool is attributed to the
platelet, with plasma containing scarcer amount or no
VEGF-A. The change in serum VEGF-A following liver
resection strongly correlated with the altered platelet count.
Serum VEGF-A was found to be significantly elevated after
a month of partial hepatectomy; intra-platelet VEGF (IP-
VEGF) showed the similar trend whereas no significant dif-
ference was observed in the level of major mitogens
including hepatocyte growth factor. The soluble VEGF
receptors as important anti-angiogenic markers were down
regulated during the on-going angiogenic phase of LR.
Conclusion: IP-VEGF in angiogenic phase might clue to
anovel therapeutic target to accelerate LR after hepatectomy.
MO-A.05 PROGNOSTIC FACTORS OF
RECURRED HEPATOCELLULAR
CARCINOMA AFTER PRIMARY
LIVER RESECTION
J. Jeong, K. Suh, K. Lee, N. Yi
Seoul National University College Of Medicine, Seoul,
SEOUL
Background: Resection is the treatment of choice for hepa-
tocellular carcinoma (HCC). However, recurrence is still a
major problem after primary resection and prognostic factors
after recurrence is not well known. So, we investigated prog-
nostic factors of recurred HCC after primary resection to
determine who had an aggressive tumor biology.
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Methods: We reviewed the patients who underwent surgical
resection for HCC between 2005 and 2011. Of a total 941
patients who underwent resection, 589 (62.5%) patients had
recurrences. Among them, 141 patients with extrahepatic
recurrences or positive margins were excluded. Finally, we
analyzed 448 patients who had intrahepatic recurrences after
curative resections.
Results: The median duration between primary resection
and recurrence was 9.0 (0.2–90.0) months. At recurrence,
353 (78.8%) patients had HCCs within Milan’s criteria.
After recurrence, 5-year disease-free survival rate was
12.8% and 5-year survival rate was 66.1%. >5 cm of
primary tumor size, <1 year of duration to recurrence, >200
of AFP level at recurrence, and beyond Milan’s criteria at
recurrence were revealed as independent poor prognostic
factors associated with disease-free survival. Whereas, only
Milan’s criteria and CTP class at recurrence were identified
as independent prognostic factors associated with overall
survival.
Conclusion: For recurred HCC after primary resection,
factors at recurrence including primary tumor size are sig-
nificantly associated with disease-free survival. Milan’s cri-
teria and CTP class at recurrence are associated with overall
survival. Therefore, it should be considered when deciding
the second-line treatment option for recurred HCC after
primary resection.
MO-B.01 GOING GREEN BEYOND THE
BORDERS: EXPANDING THE IRE KILL
ZONE WHILE CONSERVING
ELECTRICITY
S. C. Agle, Y. Li, C. A. Doughtie, C. R. Scoggins,
R. C. Martin
University Of Louisville, Louisville, KY USA
Introduction: Irreversible electroporation (IRE) is an abla-
tion technique in which short, high-voltage pulses are applied
to tissue to irreversibly permeabilize the cell membrane result-
ing in apoptosis. The objective of this study was to determine
if a secondary zone of reversible electroporation can be used to
enhance tumor cell death.
Methods: Five nude mice with orthotopic human pancreatic
adenocarcinoma (PANC1) were in each group: gemcitabine
(15 mg/kg) alone, IRE alone, gemcitabine plus IRE and a
control group. IRE was set up in a 2-probe array around the
tumor to produce 2,000 volts/cm at a rate of 90 pulses per
minute for a total of 90 pulses. Pancreas tissue slides were
measured for hypoxia via the hypoxia-inducible factor (HIF-
1a) and apoptosis via TUNEL staining. The IRE tissue was
obtained from the lateral probe margin adjacent to the abla-
tion zone and the gemcitabine only tissue was taken from the
tumor edge.
Results: The rate of hypoxia (Th area %) in the tissue
treated with IRE alone or combined with gemcitabine were
similar (45.2 ± 8.6 and 68.0 ± 15.3) and over 3 times lower
(p < 0.1) than the groups receiving only gemcitabine or no
treatment (218.8 ± 29.2 and 351.8 ± 28.4). IRE plus
gemcitabine group had an apoptotic index of 22.6% ± 7.7
which was more than 4 times higher than the IRE alone
group (4.6 ± 2.7, p < 0.01).
Conclusion: In addition to tumor cell death within the irre-
versible ablation zone the use of IRE could potentially reduce
local recurrence by allowing for increased drug administra-
tion to the cells on the periphery of the ablation zone.
MO-B.02 THE POST-SIR-SPHERES
SURGERY STUDY (P4S): ANALYSIS OF
OUTCOMES FOLLOWING HEPATIC
RESECTION OR TRANSPLANTATION IN
101 PATIENTS PREVIOUSLY TREATED
WITH SELECTIVE INTERNAL
RADIATION THERAPY (SIRT)
F. Pardo1, M. Schoen2, L. Rheun-Chuan3, D. M. Manas4,
D. R. Jeyarajah5, G. Katsanos 6, G. A. Maleux7, B. Sangro8
1Hepatobiliary, Pancreatic And Transplant Surgery,
Pamplona, NAVARRA; 2Surgery, Kalrsruhe,
BADEN-WÜRTTEMBERG; 3Interventional Radiology,
Taipei, BEITOU DISTRICT,; 4Hepatobiliary And
Transplant Surgery, Newcastle, TYNE AND WEAR;
5Surgical Oncology, Dallas, TX; 6Hepatobiliary And
Transplant Surgery, Brussels, BRUXELLES; 7Radiology,
Leuven, FLEMISH BRABANT; 8Liver Unit, Pamplona,
NAVARRA
SIRT (or radioembolisation) is primarily used as palliative
treatment for inoperable primary or metastatic liver tumours,
and as bridge-to-liver transplantation in hepatocellular carci-
noma (HCC). There have been reports of down-sizing to
surgical resection/transplantation but there are no robust
studies of safety outcomes. P4S is an international,
multicentre, retrospective study to assess outcomes associ-
ated with liver resection or transplantation following SIRT
using yttrium-90 resin microspheres (SIR-Spheres; Sirtex).
Primary endpoints were peri-operative and 90-day post-
operative morbidity and mortality. Analysis used standard
statistical methods. Data were captured on SIRT, surgery
(between 08/1998–05/2014) and follow-up on 101 patients
with either primary liver cancer (HCC: 48.5%; cholan-
giocarcinoma: 6.9%) or secondary hepatic metastases from
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colorectal (30.7%), neuroendocrine (6.9%) and other cancers
(6.9%). Resection was performed in 72 patients (71.3%;
40.6% major, 30.7% minor) and liver transplantation in 29
(28.7%). Mean interval between first SIRT and first hepatic
surgery was 8.7 months. Clavien-Dindo grade 3+ peri-/post-
operative complications were: liver failure: 7 (6.9%); wound-
specific: 4 (4.0%); cardiovascular: 0 (0%); pulmonary: 8
(7.9%); renal-specific: 2 (2.0%); other: 15 (14.9%). Cumu-
lative 90-day all-cause mortality from first hepatic surgery
was 4 (4.0%). These 4 cases were all trisectionectomies
(colorectal: 3; cholangiocarcinoma: 1) and typically had ≥1
prior chemotherapy line, pre-surgical co-morbidities and
suffered post-hepatectomy multi-organ failure including
liver failure. Future liver remnant was targeted with SIRT in
1 of the 4 cases. The safety profile of post-SIRT resection and
transplantation appears similar to that previously reported for
hepatic surgery. No deaths appear to be directly related to
SIRT.
MO-B.03 #PANCSM INITIAL
EXPERIENCE WITH CREATION OF A
TWITTER-BASED MONTHLY ONLINE
PANCREATIC CANCER CHAT
COMMUNITY
N. J. Gusani1, L. Coker3, M. H. Katz5, D. Reidy-Lagunes4,
P. Bloomston2
1Program For Liver, Pancreas, & Foregut Tumors; Penn
State Hershey Cancer Institute, Hershey, PENNSYLVANIA
USA; 2Surgical Oncology; Ohio State University,
Columbus, OH USA; 3Marketing & Communications; The
Ohio State University Comprehensive Cancer Center,
Columbus, OH USA; 4Division Of Gastrointestinal
Oncology; Memorial Sloan-Kettering Cancer Center, New
York, NY USA; 5Department Of Surgical Oncology; The
University Of Texas MD Anderson Cancer, Houston, TX
USA
Background: Pancreatic Cancer (PancCa) is a highly lethal
disease about which many myths and much nihilism exists.
Social Media (SM) is a novel medium for communication
and interaction across time and space, with microblogging
services like Twitter often used for real-time communication
in pre-arranged “chats” around a topic or disease. The
authors created a monthly Twitter-based 1-hour chat
(#PancSM) to help increase collaboration and interaction
among patients, family/caregivers, advocates, health care
providers, researchers, and charitable organizations. We
report our initial experience.
Methods: #PancSM chats are held on the first Thursday of
each month, 9–10pm ET. A moderator introduces pre-
determined topics and discussion points, facilitating interac-
tion with targeted questions. The chat progresses with free-
form discussion among participants and is united and made
searchable by use of the hashtag #PancSM in all tweets.
Metrics for each chat session and participants were derived
using online tools (Simply Measured, Followerwonk).
Results: The first three monthly #PancSM chats were lively,
with 125–262 tweets per session and 9–21 tweets per minute.
The chats had a maximal reach of 32,608, with a maximal
total exposure of 288,027 impressions. Tweeters participat-
ing in #PancSM chats initially included mostly physicians,
but by the third chat, advocacy groups and patient caregivers
were taking an important role.
Conclusions: A Twitter-based monthly Pancreatic Cancer
chat has the potential to reach large numbers of pancreatic
cancer community members and to discuss issues important
to many stakeholders. This forum is an innovative education
medium to help improve understanding and patient outcomes
in pancreatic cancer.
80 Abstracts
© 2015 The Authors
HPB © 2015 Americas Hepato-Pancreato-Biliary Association HPB 2015, 17 (Suppl. 1), 1–80
